ROR1 and neoplasm: Similarly, NBE-002 is an ADC that consists of a humanized mAb against ROR1 that is conjugated to a derivative of the highly potent anthracycline PNU-159682, which shows significant anti-tumor activity in patient-derived xenograft models of breast cancer, lung adenocarcinoma, ovarian carcinoma, and sarcomas (86).